Skip to main content
Journal cover image

The first reported case of compound heterozygous IL1RN mutations causing deficiency of the interleukin-1 receptor antagonist.

Publication ,  Journal Article
Stenerson, M; Dufendach, K; Aksentijevich, I; Brady, J; Austin, J; Reed, AM
Published in: Arthritis Rheum
December 2011

Interleukin-1 receptor antagonist (IL-1Ra) deficiency is a rare autoinflammatory disease involving neonatal onset of pustulosis, periostitis, and sterile osteomyelitis. We report the case of a 2-week-old male who presented with a swollen, erythematous left index finger and elevated serum markers of inflammation. He later developed cyclical fevers, diffuse pustular skin lesions, and thrombus formation. After not responding to broad-spectrum antimicrobial therapy and achieving only moderate success with systemic steroid therapy, he was ultimately treated with recombinant IL-1Ra, anakinra, and experienced significant clinical improvement. Sequencing of his IL1RN gene revealed that the patient was compound heterozygous for a known mutation (E77X) associated with IL-1Ra deficiency and a novel mutation in exon 2 of the gene (c.140delC; p.T47TfsX4). His case highlights IL-1Ra deficiency as an autoinflammatory disease that is distinct from neonatal-onset multisystem inflammatory disease but that also responds well to anakinra. Our patient is the first reported compound heterozygote for E77X and the novel mutation in exon 2 of the gene, the latter of which adds to what will surely be a growing database of pathologic mutations in IL1RN.

Duke Scholars

Published In

Arthritis Rheum

DOI

EISSN

1529-0131

Publication Date

December 2011

Volume

63

Issue

12

Start / End Page

4018 / 4022

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Mutation
  • Male
  • Interleukin 1 Receptor Antagonist Protein
  • Infant, Newborn
  • Humans
  • Heterozygote
  • Hereditary Autoinflammatory Diseases
  • Exons
  • Drug Therapy, Combination
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Stenerson, M., Dufendach, K., Aksentijevich, I., Brady, J., Austin, J., & Reed, A. M. (2011). The first reported case of compound heterozygous IL1RN mutations causing deficiency of the interleukin-1 receptor antagonist. Arthritis Rheum, 63(12), 4018–4022. https://doi.org/10.1002/art.30565
Stenerson, Matthew, Kevin Dufendach, Ivona Aksentijevich, Jillian Brady, Jared Austin, and Ann M. Reed. “The first reported case of compound heterozygous IL1RN mutations causing deficiency of the interleukin-1 receptor antagonist.Arthritis Rheum 63, no. 12 (December 2011): 4018–22. https://doi.org/10.1002/art.30565.
Stenerson M, Dufendach K, Aksentijevich I, Brady J, Austin J, Reed AM. The first reported case of compound heterozygous IL1RN mutations causing deficiency of the interleukin-1 receptor antagonist. Arthritis Rheum. 2011 Dec;63(12):4018–22.
Stenerson, Matthew, et al. “The first reported case of compound heterozygous IL1RN mutations causing deficiency of the interleukin-1 receptor antagonist.Arthritis Rheum, vol. 63, no. 12, Dec. 2011, pp. 4018–22. Pubmed, doi:10.1002/art.30565.
Stenerson M, Dufendach K, Aksentijevich I, Brady J, Austin J, Reed AM. The first reported case of compound heterozygous IL1RN mutations causing deficiency of the interleukin-1 receptor antagonist. Arthritis Rheum. 2011 Dec;63(12):4018–4022.
Journal cover image

Published In

Arthritis Rheum

DOI

EISSN

1529-0131

Publication Date

December 2011

Volume

63

Issue

12

Start / End Page

4018 / 4022

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Mutation
  • Male
  • Interleukin 1 Receptor Antagonist Protein
  • Infant, Newborn
  • Humans
  • Heterozygote
  • Hereditary Autoinflammatory Diseases
  • Exons
  • Drug Therapy, Combination